Developer docs
API playgroundTry for free, no card

Search company profiles

Matricelf

Full company profile

uuid000bi63

Namestring
Matricelf
Legal namestring
Matricelf Ltd.
Websiteurl
matricelf.com
Company typeenum
Public
Founded yearint
2019
Descriptiontext

Matricelf is a preclinical-stage biotechnology company developing a proprietary autologous regenerative medicine platform for central nervous system and other tissue injuries, with a lead program targeting spinal cord injury (SCI). Founded in 2019 at Tel Aviv University by Alon Sinai, PhD, and Professor Tal Dvir, the company is headquartered in Ness Ziona, Israel, and trades on the Tel Aviv Stock Exchange under the ticker MTLF.TA. The core technology combines patient-derived induced pluripotent stem cells (iPSCs) with a thermo-responsive hydrogel derived from decellularized patient omentum tissue to engineer functional 3D neural tissue implants. This fully autologous architecture is designed to eliminate immunogenicity by sourcing both the cellular and scaffold components from the same patient. The lead product is an engineered neural tissue implant intended to bridge damaged spinal tissue and restore motor and sensory function in patients with complete (ASIA-A) SCI.

Matricelf extends its platform into pipeline programs covering stroke, traumatic brain injury (TBI), myocardial infarction, and a proposed wholly-owned Parkinson's disease subsidiary, and has secured three granted U.S. patents covering omentum-based scaffolds (No. 12,514,957, valid through 2034), decellularized omentum tissue particles combined with iPSCs (No. 12,311,075, valid through January 21, 2039), and a calcium-alginate 3D bioprinting support medium (No. 12,221,621, valid through June 2039), plus an allowed application for cardiac tissue 3D printing. Manufacturing is conducted through strategic collaborations with Sheba Medical Center's Advanced Biotherapy Center and Tel Aviv Sourasky Medical Center's Institute for Advanced Cellular Therapies (I-ACT), with Cellino providing AI-driven iPSC production and CiRA Foundation supplying GMP-grade iPSCs. A 248-animal, 39-week GLP safety study completed in June 2026 showed no treatment-related toxicity, tumorigenicity, or implant migration; an IND-enabling efficacy study in 96 animals with chronic SCI is underway, with first-in-human trials targeted for 2027.

Matricelf has no commercial revenue and operates as a clinical-stage development company. Its go-to-market is anchored on clinical development partnerships with leading medical centers, an Israeli Ministry of Health-approved compassionate use program covering up to 8 SCI patients, and an FDA-aligned regulatory pathway. The company completed a USD 24.8 million PIPE financing in October 2025 with qualified and strategic investors, appointed Ron Mayron (former CEO of Teva Israel) as Chairman in February 2026, and is evaluating a potential Nasdaq listing. Revenue mechanics are not yet defined; the autologous, personalized therapy architecture points toward a future one-time-treatment reimbursement model contingent on regulatory approval.

Short descriptiontext

Matricelf is a preclinical Israeli biotechnology company developing autologous 3D neural tissue implants that combine patient-derived iPSCs with omentum-derived hydrogel to treat spinal cord injury and other neurological conditions, targeting first-in-human trials in 2027.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNess Ziona, Israel
HQ citystring
Ness Ziona
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Regenerative medicine, Tissue engineering, Cell therapy, Bioprinting technology, Stem cell therapy
Industry3 codes
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Surgical & Medical Instruments & Apparatus3841
Product category
Regenerative Medicine
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Spinal Cord Injury Treatment
TypeOne Time License
Description

Preclinical-stage company developing personalized regenerative medicine therapies. No commercial revenue yet; developing lead program for spinal cord injury treatment with planned first-in-human clinical trial in 2027.

matricelf.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Matricelf develops a proprietary autologous regenerative medicine platform that combines patient-derived induced pluripotent stem cells (iPSCs) with a personalized decellularized omentum-derived extracellular matrix hydrogel to engineer functional 3D neural tissue implants. Its lead candidate is an engineered neural tissue implant designed to bridge damaged spinal tissue and restore motor and sensory function in spinal cord injury patients, with first-in-human clinical trials targeted for 2027. Pipeline programs apply the same platform to stroke, traumatic brain injury, and myocardial infarction indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Statistically significant motor function improvement in preclinical rat studies: BBB score improved from 2.5 post-injury to 9.1 in treated group vs 5.8 in controls; 80% of treated rats showed >5 BBB points improvement vs 20% in controls
+1 more record
Product overview1 text field

Matricelf is a preclinical-stage biotechnology company developing a proprietary autologous regenerative medicine platform centered on its engineered neural tissue implant for spinal cord injury treatment. The platform combines patient-derived induced pluripotent stem cells (iPSCs) with a personalized extracellular matrix hydrogel derived from the patient's own omentum tissue to create functional 3D neural tissue implants. The core product is an engineered neural tissue implant designed to bridge damaged spinal tissue and restore function. Pipeline programs extend the platform to stroke, traumatic brain injury (TBI), and myocardial infarction. The company also develops 3D bioprinting technology using decellularized omentum tissue for broader tissue engineering applications.

Product and service1 record
1Engineered Neural Tissue Implant for Spinal Cord Injury
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-30
Description

Collaborative research agreement to evaluate combining CiRA's GMP-grade iPSCs with Matricelf's neural tissue engineering platform for scalable manufacturing. CiRA Foundation will supply iPSCs from 3 healthy donors to assess feasibility of generating engineered neural tissues using Matricelf's proprietary hydrogel platform. Success criteria include neural marker expression and functional electrical activity. Collaboration aims to develop automated, large-scale manufacturing processes to reduce production costs and improve access to regenerative therapies.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-23
Description

Strategic collaboration for GMP manufacturing of neural tissue implants and clinical trial readiness. Grants access to cleanroom facility at Advanced Biotherapy Center (ABC). Supports first-in-human clinical trial in spinal cord injury with integrated patient recruitment, manufacturing, surgical implantation, and rehabilitation within a single leading medical center.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-10-23
Description

Agreement with Institute for Advanced Cellular Therapies (I-ACT) at Tel Aviv Sourasky Medical Center for clinical manufacturing. Enables commencement of clinical-grade manufacturing of autologous neural tissue implants under GMP conditions as part of preparation for first-in-human trials in paralyzed patients.

Strategic tierCoreTypeTechnology or IntegrationAnnounced on2025-03-11
Description

Global collaboration to advance scalable production of personalized spinal cord injury treatments by combining Cellino's AI-driven Nebula platform with Matricelf's autologous regenerative technology. Cellino produced and delivered autologous iPSCs from four donors, which Matricelf used to generate functional neural tissues showing synchronized electrical activity and key neural markers. Validates compatibility and performance of Cellino's iPSCs with Matricelf's platform.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Leading 3D bioprinting platform company providing bio-inks, bioprinters, and consumables; comparable 3D bioprinting technology category with adjacent regenerative-medicine customer base.

TypeBroad incumbent
Description

Broad-incumbent neurotech competitor pursuing BCI implants for paralysis and SCI; very different modality (electronic implant vs. biological tissue) but targets overlapping SCI patient population and competes for the same payer/regulatory attention.

TypeDirect peer
Description

Pioneer in 3D bioprinting of human tissues; comparable technology stack (3D tissue fabrication) although focused on toxicology and liver tissue rather than neural implants.

TypeDirect peer
Description

Cell-therapy biotech developing OPC1 oligodendrocyte progenitor therapy for SCI alongside other CNS indications; closest U.S.-listed pure-play comparable in neural cell therapy for SCI.

TypeOthers
Description

Leading commercial supplier of iPSC-derived cell types; functionally comparable as a supplier to Matricelf's CiRA collaboration and a potential enabler/competitor for the broader iPSC-based therapeutic market.

TypeDirect peer
Description

Israel-based regenerative medicine peer developing recombinant human collagen-based bioinks and tissue implants; same Israeli ecosystem, similar decellularized biomaterial approach, with Matricelf's CTO Tamar Harel Adar previously employed there.

TypeDirect peer
Description

Cell-therapy peer (NurOwn autologous MSC platform) targeting neurological indications including SCI and ALS; similar autologous manufacturing paradigm and Israeli roots.

8Pluristem Therapeutics
TypeRegional player
Description

Israel-based cell-therapy company using placenta-derived adherent stromal cells; same Israeli biotech ecosystem and regenerative-medicine category, though uses allogeneic rather than autologous platform.

TypeDirect peer
Description

Clinical-stage biotech developing Cethrin (BA-210) and other SCI therapies targeting axonal regeneration; same lead indication (acute/subacute SCI) with overlapping regenerative mechanism.

10InVivo Therapeutics (SiteOne Therapeutics)
TypeDirect peer
Description

Direct SCI peer developing implantable biomaterial scaffolds (Neuro-Spinal Scaffold) for acute thoracic SCI; comparable clinical-stage SCI indication, although using a different (acellular polymer scaffold) approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Matricelf

Regenerative Medicinematricelf.com

Matricelf is a preclinical Israeli biotechnology company developing autologous 3D neural tissue implants that combine patient-derived iPSCs with omentum-derived hydrogel to treat spinal cord injury and other neurological conditions, targeting first-in-human trials in 2027.

What Matricelf does

Matricelf is a preclinical-stage biotechnology company developing a proprietary autologous regenerative medicine platform for central nervous system and other tissue injuries, with a lead program targeting spinal cord injury (SCI). Founded in 2019 at Tel Aviv University by Alon Sinai, PhD, and Professor Tal Dvir, the company is headquartered in Ness Ziona, Israel, and trades on the Tel Aviv Stock Exchange under the ticker MTLF.TA. The core technology combines patient-derived induced pluripotent stem cells (iPSCs) with a thermo-responsive hydrogel derived from decellularized patient omentum tissue to engineer functional 3D neural tissue implants. This fully autologous architecture is designed to eliminate immunogenicity by sourcing both the cellular and scaffold components from the same patient. The lead product is an engineered neural tissue implant intended to bridge damaged spinal tissue and restore motor and sensory function in patients with complete (ASIA-A) SCI.

Matricelf extends its platform into pipeline programs covering stroke, traumatic brain injury (TBI), myocardial infarction, and a proposed wholly-owned Parkinson's disease subsidiary, and has secured three granted U.S. patents covering omentum-based scaffolds (No. 12,514,957, valid through 2034), decellularized omentum tissue particles combined with iPSCs (No. 12,311,075, valid through January 21, 2039), and a calcium-alginate 3D bioprinting support medium (No. 12,221,621, valid through June 2039), plus an allowed application for cardiac tissue 3D printing. Manufacturing is conducted through strategic collaborations with Sheba Medical Center's Advanced Biotherapy Center and Tel Aviv Sourasky Medical Center's Institute for Advanced Cellular Therapies (I-ACT), with Cellino providing AI-driven iPSC production and CiRA Foundation supplying GMP-grade iPSCs. A 248-animal, 39-week GLP safety study completed in June 2026 showed no treatment-related toxicity, tumorigenicity, or implant migration; an IND-enabling efficacy study in 96 animals with chronic SCI is underway, with first-in-human trials targeted for 2027.

Matricelf has no commercial revenue and operates as a clinical-stage development company. Its go-to-market is anchored on clinical development partnerships with leading medical centers, an Israeli Ministry of Health-approved compassionate use program covering up to 8 SCI patients, and an FDA-aligned regulatory pathway. The company completed a USD 24.8 million PIPE financing in October 2025 with qualified and strategic investors, appointed Ron Mayron (former CEO of Teva Israel) as Chairman in February 2026, and is evaluating a potential Nasdaq listing. Revenue mechanics are not yet defined; the autologous, personalized therapy architecture points toward a future one-time-treatment reimbursement model contingent on regulatory approval.

Matricelf firmographics

Firmographics
Name
Matricelf
Legal name
Matricelf Ltd.
Website
https://matricelf.com
Company type
Public
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Matricelf is a preclinical Israeli biotechnology company developing autologous 3D neural tissue implants that combine patient-derived iPSCs with omentum-derived hydrogel to treat spinal cord injury and other neurological conditions, targeting first-in-human trials in 2027.
Ownership category
akta.pro rank

Matricelf industry classification

Industry
Product category
Regenerative Medicine
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAAAGAA
Stem Cell–Based Regenerative Therapies
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAI
Neural & Spinal Cord Regeneration
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Regenerative medicine
  • Tissue engineering
  • Cell therapy
  • Bioprinting technology
  • Stem cell therapy

Where Matricelf is headquartered

Location

Headquarters

HQ city
Ness Ziona
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Matricelf business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Spinal Cord Injury Treatment: Preclinical-stage company developing personalized regenerative medicine therapies. No commercial revenue yet; developing lead program for spinal cord injury treatment with planned first-in-human clinical trial in 2027.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Matricelf product offering

Product offering

Core offering

Matricelf develops a proprietary autologous regenerative medicine platform that combines patient-derived induced pluripotent stem cells (iPSCs) with a personalized decellularized omentum-derived extracellular matrix hydrogel to engineer functional 3D neural tissue implants. Its lead candidate is an engineered neural tissue implant designed to bridge damaged spinal tissue and restore motor and sensory function in spinal cord injury patients, with first-in-human clinical trials targeted for 2027. Pipeline programs apply the same platform to stroke, traumatic brain injury, and myocardial infarction indications.

Product overview

Matricelf is a preclinical-stage biotechnology company developing a proprietary autologous regenerative medicine platform centered on its engineered neural tissue implant for spinal cord injury treatment. The platform combines patient-derived induced pluripotent stem cells (iPSCs) with a personalized extracellular matrix hydrogel derived from the patient's own omentum tissue to create functional 3D neural tissue implants. The core product is an engineered neural tissue implant designed to bridge damaged spinal tissue and restore function. Pipeline programs extend the platform to stroke, traumatic brain injury (TBI), and myocardial infarction. The company also develops 3D bioprinting technology using decellularized omentum tissue for broader tissue engineering applications.

Differentiator

Problem solved

Functional benefit

Products and services

  • Engineered Neural Tissue Implant for Spinal Cord Injury

Quantifiable outcome

  • Statistically significant motor function improvement in preclinical rat studies: BBB score improved from 2.5 post-injury to 9.1 in treated group vs 5.8 in controls; 80% of treated rats showed >5 BBB points improvement vs 20% in controls
  • +1 more outcomes

Companies that use Matricelf

Customer profile

Segments3 records

Ideal customer profiles1 record

Matricelf technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature3 records

Matricelf partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • CiRA FoundationcoreStrategic or Co-development Partner · 30 March 2026Collaborative research agreement to evaluate combining CiRA's GMP-grade iPSCs with Matricelf's neural tissue engineering platform for scalable manufacturing. CiRA Foundation will supply iPSCs from 3 healthy donors to assess feasibility of generating engineered neural tissues using Matricelf's proprietary hydrogel platform. Success criteria include neural marker expression and functional electrical activity. Collaboration aims to develop automated, large-scale manufacturing processes to reduce production costs and improve access to regenerative therapies.
  • Sheba Medical CentercoreStrategic or Co-development Partner · 23 March 2026Strategic collaboration for GMP manufacturing of neural tissue implants and clinical trial readiness. Grants access to cleanroom facility at Advanced Biotherapy Center (ABC). Supports first-in-human clinical trial in spinal cord injury with integrated patient recruitment, manufacturing, surgical implantation, and rehabilitation within a single leading medical center.
  • Tel Aviv Sourasky Medical Center (Ichilov)coreStrategic or Co-development Partner · 23 October 2025Agreement with Institute for Advanced Cellular Therapies (I-ACT) at Tel Aviv Sourasky Medical Center for clinical manufacturing. Enables commencement of clinical-grade manufacturing of autologous neural tissue implants under GMP conditions as part of preparation for first-in-human trials in paralyzed patients.
  • CellinocoreTechnology or Integration · 11 March 2025Global collaboration to advance scalable production of personalized spinal cord injury treatments by combining Cellino's AI-driven Nebula platform with Matricelf's autologous regenerative technology. Cellino produced and delivered autologous iPSCs from four donors, which Matricelf used to generate functional neural tissues showing synchronized electrical activity and key neural markers. Validates compatibility and performance of Cellino's iPSCs with Matricelf's platform.

Scale indicators5 records

Recent moves9 records

Expansion highlights7 records

Matricelf competitors and assessment

Company assessment

Direct peers

  • BICO (CELLINK): Leading 3D bioprinting platform company providing bio-inks, bioprinters, and consumables; comparable 3D bioprinting technology category with adjacent regenerative-medicine customer base.
  • Organovo: Pioneer in 3D bioprinting of human tissues; comparable technology stack (3D tissue fabrication) although focused on toxicology and liver tissue rather than neural implants.
  • Lineage Cell Therapeutics: Cell-therapy biotech developing OPC1 oligodendrocyte progenitor therapy for SCI alongside other CNS indications; closest U.S.-listed pure-play comparable in neural cell therapy for SCI.
  • CollPlant Biotechnologies: Israel-based regenerative medicine peer developing recombinant human collagen-based bioinks and tissue implants; same Israeli ecosystem, similar decellularized biomaterial approach, with Matricelf's CTO Tamar Harel Adar previously employed there.
  • BrainStorm Cell Therapeutics: Cell-therapy peer (NurOwn autologous MSC platform) targeting neurological indications including SCI and ALS; similar autologous manufacturing paradigm and Israeli roots.
  • BioAxone Biosciences: Clinical-stage biotech developing Cethrin (BA-210) and other SCI therapies targeting axonal regeneration; same lead indication (acute/subacute SCI) with overlapping regenerative mechanism.
  • InVivo Therapeutics (SiteOne Therapeutics): Direct SCI peer developing implantable biomaterial scaffolds (Neuro-Spinal Scaffold) for acute thoracic SCI; comparable clinical-stage SCI indication, although using a different (acellular polymer scaffold) approach.

Broad incumbents

  • Neuralink: Broad-incumbent neurotech competitor pursuing BCI implants for paralysis and SCI; very different modality (electronic implant vs. biological tissue) but targets overlapping SCI patient population and competes for the same payer/regulatory attention.

Others

  • Fujifilm Cellular Dynamics: Leading commercial supplier of iPSC-derived cell types; functionally comparable as a supplier to Matricelf's CiRA collaboration and a potential enabler/competitor for the broader iPSC-based therapeutic market.

Regional players

  • Pluristem Therapeutics: Israel-based cell-therapy company using placenta-derived adherent stromal cells; same Israeli biotech ecosystem and regenerative-medicine category, though uses allogeneic rather than autologous platform.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Matricelf social profiles

Digital presence

Matricelf financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Matricelf leadership team

Management profile

Number of profiles

Profiles9 records

Matricelf subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Matricelf funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Matricelf M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Matricelf

What does Matricelf do?

Matricelf develops a proprietary autologous regenerative medicine platform that combines patient-derived induced pluripotent stem cells (iPSCs) with a personalized decellularized omentum-derived extracellular matrix hydrogel to engineer functional 3D neural tissue implants. Its lead candidate is an engineered neural tissue implant designed to bridge damaged spinal tissue and restore motor and sensory function in spinal cord injury patients, with first-in-human clinical trials targeted for 2027. Pipeline programs apply the same platform to stroke, traumatic brain injury, and myocardial infarction indications.

Is Matricelf a public or private company?

Matricelf is a public company. It is classified as public and is currently operating.

When was Matricelf founded?

Matricelf was founded in 2019. It employs 11 to 50 people.

Where is Matricelf based?

Matricelf is headquartered in Ness Ziona, Israel, in the Middle East region.

How does Matricelf make money?

One revenue line is on record: spinal Cord Injury Treatment.

Who are Matricelf's main competitors?

Direct peers on record are BICO (CELLINK), Organovo, Lineage Cell Therapeutics, CollPlant Biotechnologies, BrainStorm Cell Therapeutics, BioAxone Biosciences and InVivo Therapeutics (SiteOne Therapeutics). Neuralink is listed as a broad incumbent. Fujifilm Cellular Dynamics is listed as an others. Pluristem Therapeutics is listed as a regional player.

Does Matricelf have an API?

No public API is recorded for Matricelf.

What industry is Matricelf in?

Matricelf's product category is Regenerative Medicine. Its primary akta.pro industry code is HLAAAGAA, Stem Cell–Based Regenerative Therapies, with a secondary code of HLAAAGAI, Neural & Spinal Cord Regeneration. Its NAICS code is 541714 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & FinancialSpinal Cord Injury Clinical Trial Pipeline Expands As 25+ Companies Race To Redefine Spinal Cord Injury Treatment Landscape DelveinsightDelveInsight's Spinal Cord Injury Pipeline report covers 25+ companies and 30+ pipeline drugs, including preclinical and clinical-stage products. Matricelf Ltd. reported positive preclinical efficacy for its NewRal neural tissue transplantation, and Johns Hopkins Medicine announced feasibility findings for its MUSIC implantable ultrasound device.Simply Wall StIs Matricelf (TLV:MTLF) In A Good Position To Invest In Growth?Matricelf's cash burn increased 4.6% over the past year, with a 12-month runway from ₪16m cash and ₪15m annual burn. Its market cap of ₪86m means raising another year's cash would dilute shareholders by 18%. The company has no revenue and zero debt.PR NewswireMatricelf Continues Clinical Execution with Patient Enrollment Preparation Following GLP Safety Success and GMP Manufacturing MilestonesMatricelf received approval from Loewenstein Medical Center to collect blood samples from patients with complete thoracic spinal cord injury for its first-in-human study. The samples will generate iPSCs for the company's autologous neural implant. The approval is limited to blood collection, with implantation and trial initiation pending further regulatory approvals.BioWorldMatricelf studies neural tissue implant for spinal cord injuryMatricelf Ltd. initiated a pivotal IND-enabling efficacy study evaluating its engineered human neural tissue implant for chronic spinal cord injury. The study is the first pivotal trial for the implant, which aims to restore neural function in spinal cord injury patients.PR NewswireMatricelf Initiates IND Enabling Efficacy Study Following Positive Preclinical Results in Spinal Cord InjuryMatricelf Ltd. (TASE: MTLF), a Tel Aviv-based regenerative medicine company, has initiated a pivotal preclinical efficacy study evaluating its engineered human neural tissue implant for treating chronic spinal cord injury. The study, conducted under an FDA-discussed development framework, will enroll 96 animals and assess functional, behavioral, and histological endpoints over approximately 12 weeks. The company expects interim results in Q4 2026 and final results in Q1 2027, with successful outcomes intended to support preparations for a first-in-human clinical trial.PR NewswireMatricelf Advances Toward First in Human Trial Following Successful GLP Safety Study CompletionMatricelf Ltd., an Israeli regenerative medicine company, announced the successful completion of a comprehensive GLP safety study for its engineered neural tissue implant designed to treat spinal cord injury, with all predefined endpoints achieved with no abnormal findings. The study evaluated 248 animals over up to 39 weeks, demonstrating no treatment-related toxicity, tumor formation, or implant migration to distant organs. This milestone advances Matricelf's preparations for submitting an application to initiate a first-in-human clinical trial.BarchartSpinal Cord Injury Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Nipro Corp, Kringle Pharma, Abbvie, Neuroplast, Mitsubishi Tanabe Pharma America, Kringle PharmaDelveInsight's Spinal Cord Injury market report projects the market will grow from approximately USD 350 million in 2025 at an 18.3% CAGR through 2036, driven by advances in regenerative medicine and neurotechnology. Key recent developments include ONWARD Medical's FDA 510(k) clearance for home use of its ARC-EX System and XellSmart Biopharmaceutical's dual NMPA/FDA approvals for an off-the-shelf iPSC-derived neural regenerative cell therapy. The report covers pipeline therapies from multiple companies including Lineage Cell Therapeutics, Cellino, Matricelf, and NurExone Biologic advancing through preclinical and clinical stages.AijournMatricelf Enters Strategic Collaboration with Japan’s CiRA Foundation to Advance Next-Generation Regenerative ManufacturingMatricelf Ltd., an Israeli biotech company developing autologous engineered neural tissue therapy for spinal cord injury, has entered a collaborative research agreement with Japan's CiRA Foundation to evaluate combining CiRA's iPSCs with Matricelf's neural tissue engineering platform for scalable manufacturing. CiRA Foundation will supply iPSCs from 3 healthy donors for Matricelf to assess feasibility of generating engineered neural tissues using its proprietary hydrogel platform, with success criteria including neural marker expression and functional electrical activity. The collaboration aims to develop automated, large-scale manufacturing processes that could reduce production costs and improve access to regenerative therapies.Stock TitanMatricelf, CiRA team up on regenerative manufacturingMatricelf Ltd., a biotechnology company developing autologous engineered neural tissue therapies for spinal cord injury patients, has entered into a Collaborative Research Agreement with the CiRA Foundation in Japan to evaluate advanced manufacturing approaches for regenerative therapies. Under the agreement, the CiRA Foundation will supply iPSCs from 3 healthy donors for Matricelf to assess integration with its proprietary hydrogel platform, with the goal of developing an automated, large-scale manufacturing process for engineered neural tissues. Successful outcomes may support scalable production capabilities and cost reduction for regenerative therapies, aligning with Matricelf's strategy to broaden access to these treatments.PR NewswireMatricelf Enters Strategic Collaboration with Japan's CiRA Foundation to Advance Next-Generation Regenerative ManufacturingMatricelf Ltd., an Israeli biotechnology company developing autologous engineered neural tissue therapy for spinal cord injury patients, has entered a collaborative research agreement with Japan's CiRA Foundation to evaluate integrating GMP-grade iPSCs into its proprietary neural tissue engineering platform. The collaboration aims to assess whether combining these technologies can support automated, large-scale manufacturing of engineered neural tissues, with predefined success criteria including neural marker expression and functional electrical activity. Successful outcomes may enable scalable, cost-effective production of regenerative therapies while strengthening Matricelf's international positioning in the regenerative medicine field.